Physician profile
William Aitken
NPI 1861883563
$11,507.62
in general payments reported to CMS, 2019-2025
22 companies · $1,839 in 2025
The $1,839 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $536 · 2021: $450 · 2022: $7,082 · 2023: $1,257 · 2024: $344 · 2025: $1,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165 · Travel and Lodging: $850 · Consulting Fee: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.32 |
| Travel and Lodging | $850.13 |
| Consulting Fee | $425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $5,742.51 | 2022 | |
| Edwards Lifesciences Corporation | $1,160.24 | 2025 | Pascal |
| Medtronic, INC. | $1,054.17 | 2021-2025 | Onyx Frontier, Symplicity G3, Affera Mapping System |
| Akcea Therapeutics, INC. | $537.85 | 2020-2021 | |
| Abbott Laboratories | $519.45 | 2020-2023 | Aveir, Na |
| Janssen Pharmaceuticals, INC | $469.32 | 2021-2023 | Xarelto |
| Analog Devices INC. | $425.00 | 2025 | |
| Boston Scientific Corporation | $340.96 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $323.68 | 2022-2024 | Lifevest |
| Shockwave Medical, INC | $182.06 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Atricure, INC. | $139.14 | 2023 | |
| Cvrx, INC. | $130.22 | 2023 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $109.10 | 2023 | Inpefa |
| Pfizer INC. | $83.59 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $65.11 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $57.32 | 2022 | |
| Impulse Dynamics (USA) INC. | $45.54 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $32.28 | 2021-2022 | |
| Ancora Heart, INC. | $28.41 | 2023 | Accucinch |
| Merck Sharp & Dohme LLC | $22.21 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.75 | 2022 | |
| Endotronix, INC. | $19.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Aitken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.